


PROTAC RIPK degrader-6

Cat. No.:	HY-111870		
CAS No.:	2089205-64-9		
Molecular Formula:	C ₄₃ H ₄₈ N ₆ O ₁₁ S ₂		
Molecular Weight:	889		
Target:	PROTACs; RIP kinase		
Pathway:	PROTAC; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (112.49 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions	1 mM	1.1249 mL	5.6243 mL
		5 mM	1.1249 mL	2.2497 mL
		10 mM	0.1125 mL	0.5624 mL
	Please refer to the solubility information to select the appropriate solvent.			
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 7.5 mg/mL (8.44 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 7.5 mg/mL (8.44 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	PROTAC RIPK degrader-6 (example 1) is a Cereblon-based PROTAC targeting RIP Kinase degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder ^[1] .
IC ₅₀ & Target	Cereblon
In Vitro	PROTACs is useful for the targeted degradation of proteins and other polypeptides which on the one end binds to the cereblon and on the other end to the target protein (RIP2 kinase). By bringing the target protein in close proximity to the E3-Ligase, these compounds form a ternary complex leading to polyubiquitination of the target protein inducing its degradation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. John David Harlin, et al. Compounds for the modulation of rip2 kinase activity. WO2017046036A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA